These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2308 related articles for article (PubMed ID: 28810809)

  • 21. Good manufacturing practice-grade generation of CD19 and CD123-specific CAR-T cells using piggyBac transposon and allogeneic feeder cells in patients diagnosed with B-cell non-Hodgkin lymphoma and acute myeloid leukemia.
    Mucha M; Štach M; Kaštánková I; Rychlá J; Vydra J; Lesný P; Otáhal P
    Front Immunol; 2024; 15():1415328. PubMed ID: 39192973
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ex vivo expansion of natural killer cells from human peripheral blood mononuclear cells co-stimulated with anti-CD3 and anti-CD52 monoclonal antibodies.
    Masuyama J; Murakami T; Iwamoto S; Fujita S
    Cytotherapy; 2016 Jan; 18(1):80-90. PubMed ID: 26549384
    [TBL] [Abstract][Full Text] [Related]  

  • 23. GMP-Compliant Manufacturing of TRUCKs: CAR T Cells targeting GD
    Glienke W; Dragon AC; Zimmermann K; Martyniszyn-Eiben A; Mertens M; Abken H; Rossig C; Altvater B; Aleksandrova K; Arseniev L; Kloth C; Stamopoulou A; Moritz T; Lode HN; Siebert N; Blasczyk R; Goudeva L; Schambach A; Köhl U; Eiz-Vesper B; Esser R
    Front Immunol; 2022; 13():839783. PubMed ID: 35401506
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A new method for in vitro expansion of cytotoxic human CD3-CD56+ natural killer cells.
    Carlens S; Gilljam M; Chambers BJ; Aschan J; Guven H; Ljunggren HG; Christensson B; Dilber MS
    Hum Immunol; 2001 Oct; 62(10):1092-8. PubMed ID: 11600215
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel method to expand large numbers of CD56(+) natural killer cells from a minute fraction of selectively accessed cryopreserved cord blood for immunotherapy after transplantation.
    Vasu S; Berg M; Davidson-Moncada J; Tian X; Cullis H; Childs RW
    Cytotherapy; 2015 Nov; 17(11):1582-93. PubMed ID: 26432560
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ex vivo expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells through different receptor-ligand interactions.
    Jung D; Baek YS; Lee IJ; Kim KY; Jang H; Hwang S; Jung J; Moon YW; Park KS; Choi YS; An HJ
    J Exp Clin Cancer Res; 2021 Oct; 40(1):333. PubMed ID: 34686187
    [TBL] [Abstract][Full Text] [Related]  

  • 27. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia.
    Mardiros A; Dos Santos C; McDonald T; Brown CE; Wang X; Budde LE; Hoffman L; Aguilar B; Chang WC; Bretzlaff W; Chang B; Jonnalagadda M; Starr R; Ostberg JR; Jensen MC; Bhatia R; Forman SJ
    Blood; 2013 Oct; 122(18):3138-48. PubMed ID: 24030378
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A good manufacturing practice method to ex vivo expand natural killer cells for clinical use.
    Torelli GF; Rozera C; Santodonato L; Peragine N; D'agostino G; Montefiore E; Napolitano MR; Monque DM; Carlei D; Mariglia P; Pauselli S; Gozzer M; Bafti MS; Girelli G; Guarini A; Belardelli F; Foà R
    Blood Transfus; 2015 Jul; 13(3):464-71. PubMed ID: 25761309
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ex vivo expansion of highly cytotoxic human NK cells by cocultivation with irradiated tumor cells for adoptive immunotherapy.
    Lim SA; Kim TJ; Lee JE; Sonn CH; Kim K; Kim J; Choi JG; Choi IK; Yun CO; Kim JH; Yee C; Kumar V; Lee KM
    Cancer Res; 2013 Apr; 73(8):2598-607. PubMed ID: 23580577
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Optimization of the method to cultivate NK cells from abandoned white cells].
    Jin BL; Guo JQ; Han YP; Li F; Zhao Q; Li WL; Zhang DM; Wang H; Zhang JP
    Zhonghua Zhong Liu Za Zhi; 2016 Feb; 38(2):105-12. PubMed ID: 26899329
    [TBL] [Abstract][Full Text] [Related]  

  • 31. GMP-Compliant Universal Antigen Presenting Cells (uAPC) Promote the Metabolic Fitness and Antitumor Activity of Armored Cord Blood CAR-NK Cells.
    Liu E; Ang SOT; Kerbauy L; Basar R; Kaur I; Kaplan M; Li L; Tong Y; Daher M; Ensley EL; Uprety N; Nunez Cortes AK; Yang RZ; Li Y; Shaim H; Reyes Silva F; Lin P; Mohanty V; Acharya S; Shanley M; Muniz-Feliciano L; Banerjee PP; Chen K; Champlin RE; Shpall EJ; Rezvani K
    Front Immunol; 2021; 12():626098. PubMed ID: 33717142
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD33 Delineates Two Functionally Distinct NK Cell Populations Divergent in Cytokine Production and Antibody-Mediated Cellular Cytotoxicity.
    Hejazi M; Zhang C; Bennstein SB; Balz V; Reusing SB; Quadflieg M; Hoerster K; Heinrichs S; Hanenberg H; Oberbeck S; Nitsche M; Cramer S; Pfeifer R; Oberoi P; Rühl H; Oldenburg J; Brossart P; Horn PA; Babor F; Wels WS; Fischer JC; Möker N; Uhrberg M
    Front Immunol; 2021; 12():798087. PubMed ID: 35058934
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ex vivo expansion of CD56+ NK and NKT-like lymphocytes from peripheral blood mononuclear cells of patients with ovarian neoplasia.
    Alves PCM; De Angelo Andrade LAL; Petta CA; Lorand-Metze I; Derchain SF; Guimarães F
    Scand J Immunol; 2011 Sep; 74(3):244-252. PubMed ID: 21595734
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.
    Murad JM; Baumeister SH; Werner L; Daley H; Trébéden-Negre H; Reder J; Sentman CL; Gilham D; Lehmann F; Snykers S; Sentman ML; Wade T; Schmucker A; Fanger MW; Dranoff G; Ritz J; Nikiforow S
    Cytotherapy; 2018 Jul; 20(7):952-963. PubMed ID: 30180944
    [TBL] [Abstract][Full Text] [Related]  

  • 35. GMP-compliant, large-scale expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells in vitro and in vivo.
    Lim O; Lee Y; Chung H; Her JH; Kang SM; Jung MY; Min B; Shin H; Kim TM; Heo DS; Hwang YK; Shin EC
    PLoS One; 2013; 8(1):e53611. PubMed ID: 23326467
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
    Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
    Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapy.
    Spanholtz J; Tordoir M; Eissens D; Preijers F; van der Meer A; Joosten I; Schaap N; de Witte TM; Dolstra H
    PLoS One; 2010 Feb; 5(2):e9221. PubMed ID: 20169160
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expansion of NK Cells Using Genetically Engineered K562 Feeder Cells.
    Phan MT; Lee SH; Kim SK; Cho D
    Methods Mol Biol; 2016; 1441():167-74. PubMed ID: 27177665
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor.
    Sutlu T; Stellan B; Gilljam M; Quezada HC; Nahi H; Gahrton G; Alici E
    Cytotherapy; 2010 Dec; 12(8):1044-55. PubMed ID: 20795758
    [TBL] [Abstract][Full Text] [Related]  

  • 40. How do we manufacture clinical-grade interleukin-15-stimulated natural killer cell products for cancer treatment?
    Fernández L; Leivas A; Valentín J; Escudero A; Corral D; de Paz R; Vela M; Bueno D; Rodríguez R; Torres JM; Díaz-Almirón M; López-Collazo E; Martinez-Lopez J; Pérez-Martínez A
    Transfusion; 2018 Jun; 58(6):1340-1347. PubMed ID: 29542132
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 116.